News

Under the agreement with Chimerix, Merck will be responsible for development and commercialization of CMX157, an investigational oral nucleoside reverse transcriptase inhibitor currently in Phase I clinical development.

The companies will leverage and build upon EnviroLogix isothermal DNAblev2.0 chemistry and Douglas Scientific’s disruptive Array Tape Platform. Douglas Scientific president and COO Dan Malmstrom said the substantial

The multi-year program will study the impact of MTM intervention in the community pharmacy setting, with Walgreens expected to fund approximately $1m in in-kind services. HHS Secretary Kathleen

The patent provides the Schisandra Lignin extraction method and Schisandra-based products with market exclusivity for a period of 18 years. Renhuang Pharmaceuticals chairman and CEO Shaoming Li said

Immunomedics’ proprietary Dock-and-Lock (DNL) technology has been used to create the new anti-HIV agents. Immunomedics’ president and CEO Cynthia Sullivan said they are delighted with the collaboration with

The certification was based on the MedicsDocAssistant’s interoperability and interconnectivity with DHIN’s various data senders. DHIN’s various data sender healthcare companies include BayHealth Medical Center, Beebe Medical Center,

As part of the agreement, Myriad RBM will provide Bio-Rad with distribution rights for research purposes, to the catalog of quantitative multiplexed immunoassays present to run on the

As part of the agreement, Stiefel will acquire global rights to Toctino and Basilea’s existing distribution agreements for the drug. Basilea, which will receive an upfront payment of

The major claim is for a method of obtaining the galectin inhibitor compound, obtaining a composition for parenteral administration in an acceptable pharmaceutical carrier and administering to a